Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 6 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Myocardial Ischemia Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Myocardial Ischemia Overview | 9 | 1 |
| Pipeline Products for Myocardial Ischemia Comparative Analysis | 10 | 1 |
| Myocardial Ischemia Therapeutics under Development by Companies | 11 | 1 |
| Myocardial Ischemia Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Myocardial Ischemia Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Myocardial Ischemia Products under Development by Companies | 16 | 1 |
| Myocardial Ischemia Products under Investigation by Universities/Institutes | 17 | 1 |
| Myocardial Ischemia Companies Involved in Therapeutics Development | 18 | 10 |
| Bayer AG | 18 | 1 |
| Cellmid Limited | 19 | 1 |
| CohBar, Inc. | 20 | 1 |
| Lixte Biotechnology Holdings, Inc. | 21 | 1 |
| Miltenyi Biotec GmbH | 22 | 1 |
| NoNO, Inc. | 23 | 1 |
| Shire Plc | 24 | 1 |
| Symic Biomedical, Inc. | 25 | 1 |
| Taxus Cardium Pharmaceuticals Group Inc. | 26 | 1 |
| ViroMed Co., Ltd. | 27 | 1 |
| Myocardial Ischemia Therapeutics Assessment | 28 | 9 |
| Assessment by Monotherapy Products | 28 | 1 |
| Assessment by Target | 29 | 2 |
| Assessment by Mechanism of Action | 31 | 2 |
| Assessment by Route of Administration | 33 | 2 |
| Assessment by Molecule Type | 35 | 2 |
| Drug Profiles | 37 | 31 |
| AB-002 Drug Profile | 37 | 1 |
| Alda-1 Drug Profile | 38 | 1 |
| alferminogene tadenovec Drug Profile | 39 | 5 |
| AntimiR-199a Drug Profile | 44 | 1 |
| BAY-606583 Drug Profile | 45 | 1 |
| CMK-103 Drug Profile | 46 | 1 |
| EP-80317 Drug Profile | 47 | 1 |
| Humanin Drug Profile | 48 | 1 |
| LB-100 Drug Profile | 49 | 3 |
| Peptagon Drug Profile | 52 | 1 |
| PMC-6 Drug Profile | 53 | 1 |
| Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology Drug Profile | 54 | 1 |
| SB-030 Drug Profile | 55 | 2 |
| Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury Drug Profile | 57 | 1 |
| Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia Drug Profile | 58 | 1 |
| Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma Drug Profile | 59 | 1 |
| Small Molecules to Inhibit Mst1 for Myocardial Ischemia Drug Profile | 60 | 1 |
| Stem Cell Therapy for Cardiovascular Disease Drug Profile | 61 | 1 |
| Stem Cell Therapy for Cardiovascular Diseases Drug Profile | 62 | 2 |
| VM-202 Drug Profile | 64 | 4 |
| Myocardial Ischemia Dormant Projects | 68 | 1 |
| Myocardial Ischemia Discontinued Products | 69 | 1 |
| Myocardial Ischemia Product Development Milestones | 70 | 13 |
| Featured News &Press Releases | 70 | 1 |
| May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities | 70 | 1 |
| Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell &Gene Therapy Forum | 71 | 1 |
| Sep 03, 2014: Taxus Cardium to Present at the Rodman &Renshaw 16th Annual Global Investment Conference in New York City | 72 | 1 |
| Aug 13, 2014: Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Journal of Cardiovascular Pharmacology | 72 | 1 |
| Jun 12, 2014: Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention | 73 | 1 |
| Jan 27, 2014: Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings | 73 | 1 |
| May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy | 74 | 2 |
| Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease | 76 | 2 |
| Oct 25, 2012: Cytori Announces Japanese Approval For Clinical Studies Of Cardiovascular And Chronic Liver Disease Cell Therapy | 78 | 1 |
| Mar 20, 2012: Cardium Therapeutics Initiates Generx Phase III Clinical Registration Study | 78 | 1 |
| Feb 28, 2012: Baxter Initiates Phase III Adult Stem Cell Clinical Trial For Chronic Cardiac Condition | 79 | 1 |
| Jun 15, 2011: Cardium Therapeutics's Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance For Phase III Registration Clinical Study For Coronary Artery Disease | 80 | 2 |
| Nov 03, 2010: Cardium Awarded Grant Under QTDP Program | 82 | 1 |
| Dec 08, 2006: Cardium's Generx Advances To Phase III Following Meeting With FDA | 82 | 1 |
| Appendix | 83 | 2 |
| Methodology | 83 | 1 |
| Coverage | 83 | 1 |
| Secondary Research | 83 | 1 |
| Primary Research | 83 | 1 |
| Expert Panel Validation | 83 | 1 |
| Contact Us | 83 | 1 |
| Disclaimer | 84 | 1 |